hero section gradient
15 handpicked stocks

Clinical Trial Tech: Growth vs Competition Risks

Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.

Author avatar

Han Tan | Market Analyst

Published on October 29

About This Group of Stocks

1

Our Expert Thinking

Thermo Fisher's £8.88 billion acquisition of Clario signals a pivotal shift towards digital solutions in drug development. This massive investment highlights how pharmaceutical giants are prioritising technology companies that can streamline clinical trials and accelerate research through data analytics and AI-powered tools.

2

What You Need to Know

This group focuses on companies at the intersection of healthcare and technology, providing essential software platforms, data analytics, and AI tools for drug discovery. These businesses benefit from the growing demand for efficient, data-integrated pharmaceutical research as the industry undergoes digital transformation.

3

Why These Stocks

Each company was handpicked by professional analysts for their role in modernising drug development. From computational platforms to clinical trial management systems, these firms provide the specialised technology that major pharmaceutical companies increasingly rely on to bring medicines to market faster.

Why You'll Want to Watch These Stocks

🔬

Industry Transformation Underway

The pharmaceutical industry is rapidly digitising, with major players like Thermo Fisher investing billions in data-driven solutions. Companies providing these essential technologies are positioned at the centre of this massive shift.

🤖

AI-Powered Drug Discovery

These companies are using artificial intelligence and advanced analytics to revolutionise how medicines are discovered and developed. This technology could dramatically reduce the time and cost of bringing new treatments to market.

Expert-Validated Opportunity

Professional analysts have identified these firms as key beneficiaries of the pharmaceutical industry's digital transformation. Each company plays a crucial role in modernising clinical trials and drug development processes.

Frequently Asked Questions